vs
Side-by-side financial comparison of EVERSPIN TECHNOLOGIES INC. (MRAM) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($18.3M vs $14.9M, roughly 1.2× EVERSPIN TECHNOLOGIES INC.). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -3.0%, a 1.0% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs -25.6%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs -10.1%).
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
MRAM vs RMTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.9M | $18.3M |
| Net Profit | $-296.0K | $-554.0K |
| Gross Margin | 52.7% | 21.1% |
| Operating Margin | 29.0% | -2.2% |
| Net Margin | -2.0% | -3.0% |
| Revenue YoY | 13.2% | -25.6% |
| Net Profit YoY | — | 26.7% |
| EPS (diluted) | $-0.01 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $14.9M | — | ||
| Q4 25 | $14.8M | $18.3M | ||
| Q3 25 | $14.1M | $15.9M | ||
| Q2 25 | $13.2M | $16.1M | ||
| Q1 25 | $13.1M | $18.9M | ||
| Q4 24 | $13.2M | $24.7M | ||
| Q3 24 | $12.1M | $28.3M | ||
| Q2 24 | $10.6M | $25.8M |
| Q1 26 | $-296.0K | — | ||
| Q4 25 | $1.2M | $-554.0K | ||
| Q3 25 | $54.0K | $-1.8M | ||
| Q2 25 | $-670.0K | $-1.5M | ||
| Q1 25 | $-1.2M | $-1.5M | ||
| Q4 24 | $1.2M | $-756.0K | ||
| Q3 24 | $2.3M | $1.7M | ||
| Q2 24 | $-2.5M | $343.0K |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 50.8% | 21.1% | ||
| Q3 25 | 51.3% | 14.3% | ||
| Q2 25 | 51.3% | 15.6% | ||
| Q1 25 | 51.4% | 16.1% | ||
| Q4 24 | 51.3% | 14.7% | ||
| Q3 24 | 49.2% | 22.0% | ||
| Q2 24 | 49.0% | 17.6% |
| Q1 26 | 29.0% | — | ||
| Q4 25 | -7.2% | -2.2% | ||
| Q3 25 | -11.0% | -9.9% | ||
| Q2 25 | -14.9% | -8.4% | ||
| Q1 25 | -14.7% | -7.2% | ||
| Q4 24 | -11.8% | -2.1% | ||
| Q3 24 | -17.5% | 6.8% | ||
| Q2 24 | -26.5% | 2.0% |
| Q1 26 | -2.0% | — | ||
| Q4 25 | 8.1% | -3.0% | ||
| Q3 25 | 0.4% | -11.0% | ||
| Q2 25 | -5.1% | -9.3% | ||
| Q1 25 | -8.9% | -8.0% | ||
| Q4 24 | 9.2% | -3.1% | ||
| Q3 24 | 18.8% | 5.9% | ||
| Q2 24 | -23.5% | 1.3% |
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $0.05 | $-0.01 | ||
| Q3 25 | $0.00 | $-0.05 | ||
| Q2 25 | $-0.03 | $-0.05 | ||
| Q1 25 | $-0.05 | $-0.04 | ||
| Q4 24 | $0.07 | $-0.02 | ||
| Q3 24 | $0.10 | $0.04 | ||
| Q2 24 | $-0.12 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.5M | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.2M | $37.0M |
| Total Assets | $83.2M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.5M | — | ||
| Q4 25 | $44.5M | $10.7M | ||
| Q3 25 | $45.3M | $13.6M | ||
| Q2 25 | $45.0M | $12.5M | ||
| Q1 25 | $42.2M | $11.4M | ||
| Q4 24 | $42.1M | $15.7M | ||
| Q3 24 | $39.6M | $12.3M | ||
| Q2 24 | $36.8M | $11.9M |
| Q1 26 | $70.2M | — | ||
| Q4 25 | $68.9M | $37.0M | ||
| Q3 25 | $65.8M | $37.0M | ||
| Q2 25 | $64.1M | $30.4M | ||
| Q1 25 | $63.0M | $31.5M | ||
| Q4 24 | $62.6M | $32.6M | ||
| Q3 24 | $59.3M | $29.1M | ||
| Q2 24 | $55.4M | $23.5M |
| Q1 26 | $83.2M | — | ||
| Q4 25 | $84.6M | $57.1M | ||
| Q3 25 | $80.3M | $57.5M | ||
| Q2 25 | $78.9M | $52.6M | ||
| Q1 25 | $80.2M | $54.0M | ||
| Q4 24 | $77.8M | $59.2M | ||
| Q3 24 | $72.6M | $57.1M | ||
| Q2 24 | $64.6M | $53.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $570.0K | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $570.0K | — | ||
| Q4 25 | $2.6M | $2.3M | ||
| Q3 25 | $881.0K | $-1.3M | ||
| Q2 25 | $5.0M | $1.8M | ||
| Q1 25 | $1.4M | $-3.5M | ||
| Q4 24 | $3.8M | $865.0K | ||
| Q3 24 | $2.8M | $4.3M | ||
| Q2 24 | $1.7M | $1.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-975.0K | $2.2M | ||
| Q3 25 | $543.0K | $-1.5M | ||
| Q2 25 | $3.0M | $1.7M | ||
| Q1 25 | $527.0K | $-3.5M | ||
| Q4 24 | $2.1M | $470.0K | ||
| Q3 24 | $2.8M | $4.1M | ||
| Q2 24 | $1.7M | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | 12.0% | ||
| Q3 25 | 3.9% | -9.6% | ||
| Q2 25 | 22.9% | 10.5% | ||
| Q1 25 | 4.0% | -18.8% | ||
| Q4 24 | 15.8% | 1.9% | ||
| Q3 24 | 22.9% | 14.4% | ||
| Q2 24 | 15.9% | 4.5% |
| Q1 26 | — | — | ||
| Q4 25 | 24.3% | 0.5% | ||
| Q3 25 | 2.4% | 1.4% | ||
| Q2 25 | 15.1% | 1.0% | ||
| Q1 25 | 6.9% | 0.3% | ||
| Q4 24 | 13.2% | 1.6% | ||
| Q3 24 | 0.5% | 0.7% | ||
| Q2 24 | 0.3% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 2.19× | — | ||
| Q3 25 | 16.31× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.16× | — | ||
| Q3 24 | 1.25× | 2.57× | ||
| Q2 24 | — | 4.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
